LONG-TERM RESULTS OF RADICAL PROSTATECTOMY AND ADJUVANT RADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER
Abstract
The article presents the results of a comparative study of the effect of adjuvant radiotherapy on the survival to biochemical recurrence (BCR) in patients undergoing radical prostatectomy (RP) of prostate cancer (PCa) depending on preand post-operative prognosis factors. Adjuvant radiation therapy following prostatectomy in a total focal dose of 60 Gy in patients with locally advanced prostate cancer (pT3a-b) or the localized process with positive surgical margins (rT2R1) and highly differentiated adenocarcinoma (Gleason score equal to 6 or less) according to a postoperative morphological examination significantly increases a 5-year survival to BCR by 25.7 % (p = 0.047) compared to observation.
About the Authors
S. A. Krasny
N. N. Alexandrov National Cancer Centre of Belarus, Minsk
Belarus
Belarus
Corresponding Member, D. Sc. (Medicine), Professor, Deputy Director
Lesnoy, 223040, Minsk district, Minsk region
P. D. Demeshko
N. N. Alexandrov National Cancer Centre of Belarus, Minsk
Belarus
Belarus
D. Sc. (Medicine), Head of the Department
Lesnoy, 223040, Minsk district, Minsk region
S. L. Polyakov
N. N. Alexandrov National Cancer Centre of Belarus, Minsk
Belarus
Belarus
Ph. D. (Medicine), Head of the Department
Lesnoy, 223040, Minsk district, Minsk region
E. A. Stepanovich
N. N. Alexandrov National Cancer Centre of Belarus, Minsk
Belarus
Belarus
Radiation Oncologist
Lesnoy, 223040, Minsk district, Minsk region
A. A. Minich
N. N. Alexandrov National Cancer Centre of Belarus, Minsk
Belarus
Belarus
Ph. D. (Medicine), Leading researcher
Lesnoy, 223040, Minsk district, Minsk region,
References
1. Yossepowitch O., Eggener S. E., Serio A. M., Carver B. S., Bianco F. J., Scardino P. T., Eastham J. A. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. European Urology, 2008, vol. 53, no. 5, pp. 950–959. doi.org/10.1016/j.eururo.2007.10.008
2. Partin A. W., Mangold L. A., Lamm D. M., Walsh P. C., Epstein J. I., Pearson J. D. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology, 2001, vol. 58, no. 6, pp. 843–848. doi.org/10.1016/ s0090-4295(01)01441-8
3. Bill-Axelson A., Holmberg L., Ruutu M., Häggman M., Andersson S.-O., Bratell S., Spångberg A., Busch C., Nordling S., Garmo H., Palmgren J., Adami H.-O., Norlén B. J., Johansson J.-E. Radical prostatectomy versus watchful waiting in early prostate cancer. New England Journal of Medicine, 2005, vol. 352, no. 19, pp. 1977–1984. doi.org/10.1056/nejmoa043739
4. Bill-Axelson A., Holmberg L., Ruutu M., Garmo H., Stark J. R., Busch C., Nordling S., Häggman M., Andersson S.-O., Bratell S., Spångberg A., Palmgren J., Steineck G., Adami H.-O., Johansson J.-E. Radical prostatectomy versus watchful waiting in early prostate cancer. New England Journal of Medicine, 2011, vol. 364, no. 18, pp. 1708–1717. doi.org/10.1056/ nejmoa1011967
5. Pound C. R., Partin A. W., Eisenberger M. A., Chan D. W., Pearson J. D., Walsh P. C. Natural history of progression after PSA elevation following radical prostatectomy. J.A.M.A, 1999, vol. 281, no. 17, pp. 1591–1597. doi.org/10.1001/jama.281.17.1591
6. Sineshaw H. M., Gray P. J., Efstathiou J. A., Jemal A. Declining use of radiotherapy for adverse features after radical prostatectomy: results from the National cancer data base. European Urology, 2015, vol. 68, no. 5, pp. 768–774. doi. org/10.1016/j.eururo.2015.04.003
7. Boccon-Gibod L., Djavan B., Hammerer P., Hoeltl W., Kattan M. W., Prayer-Galetti T., Teillac P., Tunn U. W. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. International Journal of Clinical Practice, 2004, vol. 58, no. 4, pp. 382–390. doi.org/10.1111/j.1368-5031.2004.00184.x
8. Moul J. W. Prostate specific antigen only progression of prostate cancer. The Journal of Urology, 2000, vol. 163, no. 6, pp. 1632–1642. doi.org/10.1016/s0022-5347(05)67511-8
9. Hamdy F. C., Donovan J. L., Lane J. A., Mason M., Metcalfe C., Holding P., Davis M., Peters T. J., Turner E. L., Martin R. M., Oxley J., Robinson M., Staffurth J., Walsh E., Bollina P., Catto J., Doble A., Doherty A., Gillatt D., Kockelbergh R., Kynaston H., Paul A., Powell P., Prescott S., Rosario D. J., Rowe E., Neal D. E. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. New England Journal of Medicine, 2016, vol. 375, no. 15, pp. 1415–1424. doi.org/10.1056/ nejmoa1606220
10. Mullins J. K., Feng Z., Trock B. J., Epstein J. I., Walsh P. C., Loeb S. The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. The Journal of Urology, 2012, vol. 188, no. 8, pp. 2219–2224. doi. org/10.1016/j.juro.2012.08.028
11. Gandaglia G., Cozzarini C., Mottrie A., Bossi A., Fossati N., Montorsi F., Briganti A. The role of radiotherapy after radical prostatectomy in patients with prostate cancer. Current Oncology Reports, 2015, vol. 17, no. 12, pp. 53. doi.org/10.1007/ s11912-015-0478-5
12. Bolla M., van Poppel H., Tombal B., Vekemans K., da Pozzo L., de Reijke T. M., Verbaeys A., Bosset J.-F., van Velthoven R., Colombel M., van de Beek C., Verhagen P., van den Bergh A., Sternberg C., Gasser T., van Tienhoven G., Scalliet P., Haustermans K., Collette L. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). The Lancet, 2012, vol. 380, no. 9858, pp. 2018–2027. doi.org/10.1016/s0140-6736(12)61253-7
13. Wiegel T., Bartkowiak D., Bottke D., Bronner C., Steiner U., Siegmann A., Golz R., Störkel S., Willich N., Semjonow A., Stöckle M., Rübe C., Rebmann U., Kälble T., Feldmann H. J., Wirth M., Hofmann R., Engenhart-Cabillic R., Hinke A., Hinkelbein W., Miller K. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. European Urology, 2014, vol. 66, no. 2, pp. 243–250. doi.org/10.1016/j.eururo.2014.03.011
14. Partin A. W., Pound C. R., Pearson J. D., Clemens J. Q., Landis P. K., Epstein J. I., Carter H. B., Walsh P. C. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology, 1994, vol. 43, no. 5, pp. 649–659. doi.org/10.1016/0090-4295(94)90180-5
Review
Views: 679
Email this article 